MRNA vs PFE: which stock is the better buy?
Moderna, Inc. and Pfizer Inc., graded by the same fixed-weight model from live fundamentals — composite score, 12-month forecast, valuation, growth and margins, side by side. As of July 6, 2026.
On today’s numbers, Pfizer Inc. grades higher — 60/100 vs 58/100. Tap either card for the full factor breakdown.
Metric by metric
| Metric | MRNA | PFE |
|---|---|---|
| TradersQuant Score | 58/100 | 60/100 ✓ |
| Price | $79.76 | $24.32 |
| 12-mo base forecast | $118.56 | $25.70 |
| Implied upside | +48.6% ✓ | +5.7% |
| Bull / bear range | $135.18 / $108.25 | $28.72 / $24.23 |
| P/E | -9.8 ✓ | 18.6 |
| Forward P/E | — | — |
| Revenue growth (YoY) | -39.2% | -1.6% ✓ |
| Gross margin | -13.9% | 69.3% ✓ |
| Market cap | $31.6B | $138.6B |
| Sector | Healthcare | Healthcare |
✓ marks the stronger reading per metric (lower is better for P/E). Figures refresh continuously; research, not financial advice.
Want the full verdict on MRNA and PFE?
The AI bull/base/bear thesis, smart-money positioning, options signals and insider activity on both — every systematic call graded in public against the S&P 500.
$0 today · cancel before day 7 and you won’t be charged
MRNA vs PFE — FAQ (2026)
Is MRNA or PFE the better buy right now?
On the live TradersQuant composite score, Pfizer Inc. (PFE) currently grades higher at 60/100 versus 58/100 for MRNA. The score weighs valuation, growth, earnings quality, momentum, the macro regime, sentiment and balance-sheet risk — open each stock's page for the full breakdown. Research, not financial advice.
Which has more 12-month upside, MRNA or PFE?
TradersQuant's 12-month base-case forecast currently implies +48.6% for MRNA and +5.7% for PFE. Both forecasts are three-scenario models (bull/base/bear) refreshed continuously and graded on our public track record.
How is this MRNA vs PFE comparison calculated?
Both stocks are scored by the same fixed-weight model — 20% valuation, 20% growth, 15% earnings quality, 15% momentum, 10% macro regime fit, 10% analyst sentiment, 10% balance-sheet risk — from live fundamentals and prices. No hand-picking: the same arithmetic runs on every stock we cover, and our systematic calls are graded in public against the S&P 500.